July 21st 2025
A quality-adjusted time without symptoms or toxicity analysis identified better outcomes for patients with RCC treated with belzutifan vs everolimus.
Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.
July 18th 2025
A personalized neoantigen vaccine may be effective in patients with clear cell renal cell carcinoma, shared David A. Braun, MD, PhD.
July 1st 2025
ALLO-316 showed significant activity and safety in patients with metastatic CD70-positive clear cell renal cell carcinoma.
June 10th 2025
A machine learning model applied to CheckMate 9ER may help predict outcomes and resistance in advanced renal cell carcinoma.
Subcutaneous Nivolumab Maintains Comparable Efficacy, Safety to IV in ccRCC
The subcutaneous formulation of nivolumab showed comparable efficacy and safety to the IV formulation in advanced clear cell renal cell carcinoma.
Real-World Data Back First-Line Avelumab and Axitinib in Advanced RCC
Avelumab in combination with axitinib was found effective and safe as frontline treatment for advanced RCC in real-world findings.
Tivozanib Combo Yields Similar PROs to Monotherapy in Advanced Clear Cell RCC
Patient-reported outcomes were consistent between patients with RCC using tivozanib/nivolumab and tivozanib monotherapy according to study findings.
Proactive Onco-Coaching Linked to Higher OS in mRCC
Proactive onco-coaching did not improve QOL but was associated with improved OS in patients with metastatic renal cell carcinoma receiving TKIs and ICIs.
Olanzapine May Address AEs From TKIs for Kidney and Other Cancers
Patients treated with tyrosine kinase inhibitors received olanzapine to address adverse effects including nausea/vomiting, anorexia, insomnia, and weight loss.
Cabozantinib Combo Maintains PFS for Advanced RCC at Follow-Up
New results uphold previous findings regarding the efficacy of cabozantinib, nivolumab, and ipilumumab arm for advanced renal cell carcinoma.
Nivolumab Plus Cabozantinib Effective Long-Term for Advanced RCC
Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.
Personalized Cancer Vaccine May Trigger Anti-Tumor Response in RCC
In a phase 1 trial, all 9 patients with renal cell carcinoma treated with a neoantigen-targeting personalized cancer vaccine showed no recurrence at data cutoff.
Opinion: Subcutaneous Nivolumab Offers an Effective Alternative to Intravenous Administration
Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion center.
Belzutifan/Cabozantinib Shows Responses, Manageable Side Effects in First-Line ccRCC
Frontline treatment with belzutifan and cabozantinib resulted in durable responses and a manageable safety profile in patients with previously untreated advanced ccRCC.
FDA OKs Subcutaneous Nivolumab in Advanced/Metastatic Solid Tumors
Nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) was approved by the FDA for subcutaneous injection across approved solid tumor indications for nivolumab (Opdivo).
NKT2152 Shows Promising Efficacy in Advanced Clear Cell Kidney Cancer
NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma.
Tivozanib Alone Outperforms Lower-Dose Tivozanib-Nivolumab Combo in Metastatic RCC
Study findings support tivozanib monotherapy for second-line treatment of certain patients with metastatic RCC, an expert said.
Belzutifan Has Durable PFS, ORR in Previously Treated Advanced Clear Cell RCC
Belzutifan improved progression-free survival and objective response rate compared to everolimus in previously treated advanced renal cell carcinoma.
Nivolumab Plus Ipilimumab Maintains Survival Benefit at 8 Years in Advanced Renal Cell Carcinoma
Compared to sunitinib, nivolumab plus ipilimumab showed increased overall survival and durable response benefits in patients with advanced renal cell carcinoma.
Higher Corticosteroid Peak Dose May Worsen Survival in Patients With Treatment-Related Adverse Events
Higher corticosteroid peak dose may worse progression-free and overall survival in several tumor types including melanoma, non-small cell lung cancer, and others.
Nivolumab Plus Tivozanib Ineffective in Improving PFS in Advanced RCC Following Prior Immune Checkpoint Inhibition
Nivolumab plus tivozanib did not improve progression-free survival in patients with advanced metastatic renal cell carcinoma after prior immune checkpoint inhibition.
Belzutifan Generates PFS Benefit in Pretreated Advanced ccRCC
The progression-free survival benefit with belzutifan was observed across subgroups of patients with pretreated advanced clear cell renal cell carcinoma.
FDA Grants Fast Track Designation to ADI-270 for Pretreated Advanced ccRCC
The CAR T-cell therapy ADI-270 received fast track designation from the FDA for pretreated advanced clear cell renal cell carcinoma.
Belzutifan Demonstrates Manageable Safety Profile in Previously Treated Advanced RCC
This analysis of patients with previously treated advanced clear cell renal cell carcinoma treated with belzutifan is the largest pooled safety dataset for a HIF-2α inhibitor.
PD-L1 Positivity May Be Linked to Shorter Overall Survival in Metastatic Papillary RCC
Findings from a retrospective study may shed light on the prognostic value of PD-L1 expression in metastatic papillary renal cell carcinoma.
TKIs Exhibit Modest Activity in Advanced RCC After Lenvatinib Exposure
Patients with advanced renal cell carcinoma with previous exposure to lenvatinib derived modest benefit with tyrosine kinase inhibitors.
Salvage Treatment Combo Improves Treatment-Free Survival in RCC
Patients with advanced clear cell renal cell carcinoma who received salvage treatment with nivolumab plus ipilimumab after progressing on nivolumab alone had significant treatment-free survival rates.
BLA for Subcutaneous Nivolumab Accepted by the FDA for Advanced/Metastatic Solid Tumors
A biologics license application has been accepted by the FDA for subcutaneous nivolumab to treat adult patients eligible for approved solid tumor nivolumab indications
Radiotherapy May Locally Control RCC Without Surgical Resection
Patients with renal cell carcinoma who did not undergo surgical resection and were treated with stereotactic ablative body radiotherapy experienced high local control rates with an acceptable side effect profile.
Belzutifan Delays Progression, Improves QoL in Advanced Kidney Cancer
Treatment with belzutifan for advanced/metastatic clear cell renal cell carcinoma delayed worsening symptoms and improved quality of life.
End-of-Life Immunotherapy Use Increasing in Advanced Melanoma, RCC, NSCLC
The rate of initiating immunotherapy towards the end of life in patients with advanced cancers, including renal cell carcinoma, melanoma, and non-small cell lung cancer, is increasing over time.
12-Week Dosing Schedule for Ipilimumab/Nivolumab May Reduce Grade 3-5 TRAEs in Advanced RCC
A modified dosing schedule may make treatment with ipilimumab plus nivolumab more tolerable for patients with advanced renal cell carcinoma.
FDA Approves Belzutifan for Patients With Advanced Renal Cell Carcinoma
The FDA has approved belzutifan to treat patients with advanced renal cell carcinoma (RCC) who have already undergone PD-1 or PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor.
Lenvatinib/Pembrolizumab Generates Lasting Responses in Advanced Kidney Cancer
The duration of response was 39.2 months among patients with 1 metastatic site treated in the combination arm vs 29.5 months for patients given sunitinib.
Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL
Q&A: Nursing Considerations From Immune Cell Effector Therapy Experts
Proactive Rash Management Vital for PI3K, AKT Inhibition in Breast Cancer
Understanding How On-Target and Off-Target ADC Toxicities Work